Miller Financial Services LLC Purchases Shares of 25,000 CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Miller Financial Services LLC acquired a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the fourth quarter, Holdings Channel.com reports. The firm acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $26,000.

Several other institutional investors have also recently modified their holdings of CTMX. Traphagen Investment Advisors LLC bought a new stake in CytomX Therapeutics in the 4th quarter worth approximately $31,000. US Bancorp DE purchased a new position in shares of CytomX Therapeutics during the third quarter worth approximately $40,000. Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $104,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of CytomX Therapeutics by 17.3% during the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after purchasing an additional 41,949 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Trading Down 7.4 %

Shares of NASDAQ:CTMX opened at $0.62 on Wednesday. The company has a 50-day moving average price of $0.83 and a 200-day moving average price of $1.01. The company has a market cap of $48.55 million, a price-to-earnings ratio of 3.65 and a beta of 1.05. CytomX Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. As a group, research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on CTMX. StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, CytomX Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $5.02.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.